Virtual Library
Start Your Search
So Mye Koo
Author of
-
+
EP1.12 - Small Cell Lung Cancer/NET (ID 202)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.12-28 - Anticancer Effects of Imipramine, Repositioned Drug, for Small Cell Lung Cancer (Now Available) (ID 273)
08:00 - 18:00 | Author(s): So Mye Koo
- Abstract
Background
Drug reposition is one of the blue oceans on discovery of new drugs. Anticancer new drugs by reposition are also vigorous mining area by in vivo, in vitro and in silico. Treatment of small cell lung cancer (SCLC) is restricted due to lack of chemotherapeutic agents. Imipramine, a challenging drug for SCLC was discovered by in silico reposition recently. We tried imipramine to the patients who diagnosed SCLC after 1st line chemotherapy
Method
From July of 2013 to December of 2015, patients who diagnosed SCLC were enrolled. All of them were treated 1st line combination chemotherapy, platinum and etoposide and some of them were done radiotherapy to main lesion. After chemotherapy or combined radiation therapy, imipramine was prescribed 25-75mg according to patient’s tolerance alternately.
Result
Fifteen patients were participated, 6 (40%) of them were limited, 9 (60%) of them were extensive stage, but more limited stage in imipramine group compare to not prescribed group (4 to 2). All of them were smokers, 12 were man (80%), mean age was 64.6. Classified by TNM stage, stage 3 was 8, stage 4 was 7. There were no differences of age, performance status, cancer stage, chemotherapy and radiation. Amount and duration of imipramine, the prescribed group, was mean 55 mg, and 9 month. Survival of two groups was imipramine prescribed group, 22 ± 6.3 month, and not prescribed group 13.0 ± 2.8 month. (P=0.105)
Conclusion
Trial of imipramine is one of the promising agent to control or maintenance of neuroendocrine tumor, especially SCLC.
